Drugs / intravenous immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06009042 | Jul 2022 → Jun 2024 | hemorrhagic fever-renal syndrome | Tongji Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous immunoglobulin | “The dose of IVIG(intravenous immunoglobulin) is 20g/d.” NCT06009042 ↗ |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06009042 ↗ |
| Modality | Protein / enzyme biologic | “IVIG(intravenous immunoglobulin)” NCT06009042 ↗ |